The industry built on a number you were never given

Somewhere right now it is three in the morning and a man is reading an advert.

He is not stupid. He is not gullible. He has, in fact, been carrying a specific worry since he was about thirteen, has never once said it out loud, has never seen a reliable figure, and has just been served a page that speaks to that worry with total confidence and a money-back guarantee.

That is not a marketing problem. That is a market, and it is worth billions, and it exists in the exact space left empty by the fact that nobody ever told him the number.

So let us do the thing the adverts never do, which is look at what the peer-reviewed literature actually says about each of these products, in order, without flinching.

Surgery: the honest arithmetic

In 2008, Yoram Vardi's group published a systematic review in *European Urology* covering four decades of penile enhancement procedures performed on men with normal anatomy. It is the closest thing this field has to a reckoning, and it is not ambiguous.

The headline: enhancement surgery can generally produce 1 to 2 cm of additional length, and around 2.5 cm of girth.

Now the rest of the paragraph, which never makes it into the brochure. The review reported, frequently across the studies it surveyed: penile deformity. Paradoxical shortening — that is, an operation for length producing a shorter penis. Disagreeable scarring. Granuloma formation. Migration of injected material. Sexual dysfunction.

And satisfaction. Short-term and long-term patient satisfaction after these procedures was described, in the review's own framing, as disappointing in most of the studies examined.

Read that back as a trade. You are offered one to two centimetres. You are exposed to a documented risk of deformity, scarring, migration and dysfunction. And the men who took the trade before you, on average, were not happy afterwards.

Everything else, briefly

The non-surgical market is larger, cheaper and almost entirely unevidenced. Working through it:

1. —Pills and supplements. There is no oral compound with credible evidence of increasing penis size. None. The category persists because supplements are regulated as food rather than as medicine in most jurisdictions, which means a product can be sold without ever demonstrating it does anything. Some contain undisclosed pharmaceutical ingredients, which is a genuine safety issue rather than merely a waste of money.
2. —Vacuum pumps. These do something real — they draw blood into the tissue, producing a temporary swelling — and they have a legitimate clinical role in erectile dysfunction and in rehabilitation after certain treatments. What they do not do is produce permanent enlargement. Used aggressively they can cause bruising, burst blood vessels and tissue damage.
3. —Extenders and traction devices. The most defensible category, in that there is at least a plausible mechanism and some clinical use in specific conditions such as Peyronie's disease. In healthy men the evidence for meaningful gain is thin, and the protocols involved require wearing a traction device for hours a day, every day, for many months. That is the honest version of the offer.
4. —Jelqing and manual exercises. No evidence base whatsoever. Case reports exist of injury from repetitive forceful manipulation, including vascular damage and scarring. This is the one that gets passed between teenagers for free, which makes it the most widely practised and the least examined.
5. —Injectable fillers. Increase girth temporarily. Migration, nodule formation and asymmetry are documented complications, and the material does not stay where it was put indefinitely.

There is a pattern in that list worth naming. The interventions with the best safety profiles are the ones that do the least, and the interventions that do the most are the ones with the worst outcomes. That is not a coincidence or a gap in the research — it is what it looks like when a market is selling a solution to a problem that is not physically located where the product is being applied.

Sixty-seven men in Florence

I keep coming back to the Mondaini study, and I am going to bring it up again here because in this context it stops being poignant and becomes an indictment.

Sixty-seven men presented at a urology clinic requesting surgical lengthening. Every one was measured. None of them was short. None had any anatomical abnormality.

Now consider what happens to those sixty-seven men in a country with a less careful clinic, or with a private cosmetic-surgery market and an advertising budget. They do not get measured against a reference range and told they are normal. They get quoted a price.

The industry's core competency is not lengthening. It is not measuring. Every step of a well-run enhancement funnel is designed to move a man from anxiety to purchase without a reference distribution ever entering the room, because the reference distribution is the single thing that would end the transaction.

This is why the international position papers on managing men who complain of a small penis all start from the same place: measure the patient, show him where he sits, and treat the distress rather than the anatomy. Reassurance and psychological support, not a scalpel. That guidance exists because the field watched what happened when it was ignored.

The one intervention with an excellent evidence base

There is a treatment for this that works, costs nothing, and has been sitting in the literature for twenty years while the market sold pills over the top of it.

Being shown the actual distribution.

That is it. Measure, compare against a clinician-derived nomogram, explain what the spread means, and for a large majority of men the distress resolves or substantially reduces — because the belief driving it was factually wrong and had never once been tested against data.

It does not work for everyone. A minority have genuine body dysmorphic disorder about this specific feature, and for them information alone is not enough; the condition is well characterised and it responds to actual psychological treatment, not to reassurance and not to surgery. That distinction matters and I do not want to flatten it.

But for the ordinary case — the man at three in the morning with the advert open — the effective intervention is a number he has never been given and a spread he has never seen. It is available for free. It is on this website. It is on the NHS website. It is in every one of the studies linked at the bottom of this page.

The industry's entire margin lives in the gap between that fact and the fact that nobody ever tells him.

If you take one thing from this piece, make it this. Before you spend money, spend ten minutes with a nomogram. If, having seen where you actually sit, the distress is still there — and for some men it genuinely will be — that is real, and it is worth taking to a doctor or a therapist, who will take it seriously and who has treatments that address what is actually happening.

What it is not worth is a credit card at three in the morning.